News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EBS Technologies Receives CE Mark for Its Brain Stimulation Device



6/5/2013 7:06:40 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EBS Technologies Receives CE Marking for Its NEXT WAVE™ Brain Stimulation Device

BERLIN--(BUSINESS WIRE)-- EBS Technologies GmbH, an emerging medical device company developing the revolutionary NEXT WAVE™ brain stimulation platform for treatment of neurological disorders caused by stroke and brain injury, announced today that it has received CE marking for NEXT WAVE™ and expects to begin commercialization in Europe immediately as the result of closing a Series “B” financing round of $3.9 million (€3,0 million) from existing investors: including lead investor Earlybird Venture Partners, High-Tech Gründerfonds (HTGF), and Brandenburg Capital. Total investment in EBS Technologies is $8.7 million (€6,7 million).

“There is a very significant unmet clinical need for the treatment of vision impairment caused by a neurological disorder such as a stroke,” said Ulf Pommerening, CEO of EBS Technologies. “For example, stroke is the world’s third-leading cause of death as well as the leading cause of serious, long-term disability. There are more than 10 million stroke survivors with long-term disability in Europe and the U.S. Three out of five of these disabled persons are potentially treatable with our non-invasive EBS Next Wave™ therapy.

“We are extremely pleased that our existing investors, lead by Earlybird Venture Partners, increased their commitment to EBS, based on strong clinical results with our low-risk, non-invasive NEXT WAVE™ system,” added Pommerening. “With this Series B cash infusion, we have already begun a limited launch of the device to key opinion-leading neurologists in Europe.”

About Next Wave™

The NEXT WAVE™ technology enables a unique revitalization of selective communication paths between neurological cells, which may have been lost due to brain injury caused by trauma, stroke or tumor resection. The non-invasive therapy utilizing the patented NEXT WAVE™ technology is clinically validated to restore vision impairment by 20 to 30 percent after brain dysfunction. In addition, glaucoma patients have shown to benefit from the NEXT WAVE™ technology.

NOTE: NEXT WAVE™ is approved for sale in Europe; it is not approved for sale or investigational use in the U.S.

Contact:

Ronald Trahan Associates Inc.

Ronald Trahan, APR, +1-508-359-4005, ext. 108



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES